# US 2006/0040991 A1 · Pharmaceutical presentation form for oral administration of a poorly soluble active compound, process for its preparation and kit

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2006/0040991 A1
- Document ID: US20060040991A1
- Status: Published application
- Kind: A1
- Application number: 11/169,407
- Filed: 2005-06-29
- Published: 2006-02-23
- Earliest claimed: 2004-06-29
- Assignees: Baxter International Inc.; Baxter Healthcare S.A.
- Inventors: Berthold Roessler
- Web page: https://patentgrep.com/patent/US20060040991A1

## CPC

- A61K 31/4439: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465)
- A61P 35/00: Antineoplastic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention relates to a pharmaceutical presentation form for the oral administration of indibulin in the form of an aqueous drink solution, and a method for its preparation.

## Claims

### Claim 1

A pharmaceutical presentation form comprising the poorly soluble active compound indibulin for oral administration, obtainable by dissolving indibulin in or with a highly concentrated organic acid which is physiologically tolerable per se in diluted form, and subsequent dilution by addition of water to a physiologically tolerable concentration of the organic acid, indibulin being present in the form of a supersaturated solution.

### Claim 2 (depends on 1)

The pharmaceutical presentation form according to claim 1, wherein the organic acid is lactic acid.

### Claim 3 (depends on 1)

The pharmaceutical presentation form according to claim 1, wherein the dissolving of the active compound takes place in an about 50% to about 90% by weight organic acid.

### Claim 4 (depends on 1)

The pharmaceutical presentation form according to claim 1, wherein after diluting with water the concentration of the organic acid is less than about 20% by weight.

### Claim 5 (depends on 4)

The pharmaceutical presentation form according to claim 4, wherein after diluting with water the concentration of the organic acid is in the range from about 5% to about 15% by weight.

### Claim 6 (depends on 1)

The pharmaceutical presentation form according to claim 1, wherein after diluting with water the concentration of the active compound indibulin is in the range from about 0.2 mg/ml to about 2 mg/ml.

### Claim 7 (depends on 6)

The pharmaceutical presentation form according to claim 6, wherein after diluting with water the concentration of the active compound indibulin is in the range from about 0.5 mg/ml to about 1.5 mg/ml.

### Claim 8 (depends on 1)

The pharmaceutical presentation form according to claim 1, wherein optionally common excipients and additives are added.

### Claim 9 (depends on 1)

The pharmaceutical presentation form according to claim 1, wherein an aqueous solution comprising taste ingredients is used for diluting.

### Claim 10 (depends on 9)

the pharmaceutical presentation form according to claim 9, wherein the aqueous solution comprising taste ingredients is an aqueous solution of glucose and at least one flavoring.

### Claim 11 (depends on 10)

The pharmaceutical presentation form according to claim 10, wherein the flavoring is maracuja flavoring.

### Claim 12 (depends on 1)

The pharmaceutical presentation form according to claim 1, wherein the presentation form has a physical stability of about 2 hours.

### Claim 13 (depends on 1)

The pharmaceutical presentation form according to claim 1, which is a drink solution.

### Claim 14

A method for the preparation of a pharmaceutical presentation form comprising the poorly soluble active compound indibulin for oral administration, wherein the active compound indibulin is dissolved in a highly concentrated organic acid which is physiologically tolerable in diluted form, and subsequently the solution thus obtained is diluted by addition of water to a physiologically tolerable concentration of the organic acid, indibulin being present in the form of a supersaturated solution.

### Claim 15 (depends on 14)

The method according to claim 14, wherein the organic acid is lactic acid.

### Claim 16 (depends on 14)

The method according to claim 14, wherein the dissolving of the active compound is carried out in or with an about 50% to about 90% by weight organic acid.

### Claim 17 (depends on 14)

The method according to claim 14, wherein after diluting with water the concentration of the organic acid is less than about 20% by weight.

### Claim 18 (depends on 17)

The method according to claim 17, wherein after diluting with water the concentration of the organic acid is in the range from about 5% to about 15% by weight.

### Claim 19 (depends on 14)

The method according to claim 14, wherein after diluting with water the concentration of the active compound indibulin is in the range from about 0.2 mg/ml to about 2 mg/ml.

### Claim 20 (depends on 19)

The method according to claim 19, wherein after diluting with water the concentration of the active compound indibulin is in the range from about 0.5 mg/ml to about 1.5 mg/ml.

### Claim 21 (depends on 14)

The method according to claim 14, wherein the pharmaceutical presentation form further comprises common excipients and additives.

### Claim 22 (depends on 14)

The method according to claim 14, wherein an aqueous solution comprising taste ingredients is used for diluting.

### Claim 23 (depends on 22)

The method according to claim 22, wherein the aqueous solution comprising taste ingredients is an aqueous solution of glucose and at least one flavoring.

### Claim 24 (depends on 23)

The method according to claim 23, wherein the flavoring is a maracuja flavoring.

### Claim 25 (depends on 14)

The method according to claim 14, wherein the presentation form thus prepared has a physical stability of about 2 hours.

### Claim 26 (depends on 14)

The method according to claim 14, wherein the presentation form thus prepared is a drink solution.

### Claim 27 (depends on 1)

A kit for the preparation of a pharmaceutical presentation form of claim 1, the kit comprising:
a specified amount of the active compound indibulin;
a specified amount of a highly concentrated organic acid; and
a specified amount of water.

### Claim 28 (depends on 27)

The kit according to claim 27 further comprising taste ingredients.

### Claim 29 (depends on 27)

The kit according to claim 27, wherein the organic acid is lactic acid.

### Claim 30 (depends on 27)

The kit according to claim 27, wherein the highly concentrated acid has a concentration in the range from about 50% to about 90% by weight.

### Claim 31 (depends on 27)

The kit according to claim 27, wherein the specified amount of water is calculated such that after diluting with water the concentration of the organic acid is less than about 20% by weight.

### Claim 32 (depends on 31)

The kit according the claim 31, wherein the specified amount of water is calculated such that after diluting with water the concentration of the organic acid is in the range from about 5% to about 15% by weight.

### Claim 33 (depends on 27)

The kit according to claim 27, wherein the specified amount of water is calculated such that after diluting with water the concentration of the active compound indibulin is in the range from about 0.2 mg/ml to about 2 mg/ml.

### Claim 34 (depends on 33)

The kit according to claim 33, wherein the specified amount of water is calculated such that after diluting with water the concentration of the active compound indibulin is in the range from about 0.5 mg/ml to about 1.5 mg/ml.

### Claim 35 (depends on 27)

The kit according to claim 27, wherein the water further comprises common excipients and additives.

### Claim 36 (depends on 35)

The kit according to claim 35, wherein the water for diluting comprises one or more taste ingredients.

### Claim 37 (depends on 36)

The kit according to claim 36, wherein the water for diluting comprises glucose and at least one flavoring.

### Claim 38 (depends on 37)

The kit according to claim 37, wherein the water for diluting contains maracuja flavoring.

### Claim 39 (depends on 27)

The kit according to claim 27, wherein the presentation form to be prepared thereby has a physical stability of about 2 hours.

### Claim 40 (depends on 27)

The kit according to claim 27, wherein the presentation form to be prepared thereby is a drink solution.
